1 Study Coverage 1.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Introduction 1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Outlook 2017 VS 2022 VS 2028 1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size for the Year 2017-2028 1.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size for the Year 2017-2028 1.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Non-Alcoholic Steatohepatitis (NASH) Drugs in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics 1.4.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends 1.4.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers 1.4.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges 1.4.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Non-Alcoholic Steatohepatitis (NASH) Drugs by Type 2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment by Type 2.1.1 Vitamin E & Pioglitazone 2.1.2 Obeticholic Acid (OCA) 2.1.3 Elafibranor 2.1.4 Selonsertib & Cenicriviroc 2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017, 2022 & 2028) 2.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028) 2.4 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017, 2022 & 2028) 2.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028) 3 Non-Alcoholic Steatohepatitis (NASH) Drugs by Application 3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment by Application 3.1.1 Hospital Pharmacy 3.1.2 Online Provider 3.1.3 Retail Pharmacy 3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017, 2022 & 2028) 3.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028) 3.4 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017, 2022 & 2028) 3.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028) 4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Competitor Landscape by Company 4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Company 4.1.1 Top Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Ranked by Revenue (2021) 4.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Player (2017-2022) 4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Concentration Ratio (CR) 4.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Non-Alcoholic Steatohepatitis (NASH) Drugs in 2021 4.2.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Headquarters, Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Type 4.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Headquarters and Area Served 4.3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Company 4.5.1 Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in United States, Ranked by Revenue (2021) 4.5.2 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2020, 2021 & 2022) 5 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region 5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2017-2028) 5.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2017-2022 5.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028 6.1.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028 6.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028 6.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 AstraZeneca 7.1.1 AstraZeneca Company Details 7.1.2 AstraZeneca Business Overview 7.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.1.5 AstraZeneca Recent Development 7.2 Conatus Pharmaceuticals 7.2.1 Conatus Pharmaceuticals Company Details 7.2.2 Conatus Pharmaceuticals Business Overview 7.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.2.5 Conatus Pharmaceuticals Recent Development 7.3 Enzo Biochem 7.3.1 Enzo Biochem Company Details 7.3.2 Enzo Biochem Business Overview 7.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.3.5 Enzo Biochem Recent Development 7.4 Galmed Pharmaceuticals 7.4.1 Galmed Pharmaceuticals Company Details 7.4.2 Galmed Pharmaceuticals Business Overview 7.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.4.5 Galmed Pharmaceuticals Recent Development 7.5 Genfit 7.5.1 Genfit Company Details 7.5.2 Genfit Business Overview 7.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.5.5 Genfit Recent Development 7.6 Gilead 7.6.1 Gilead Company Details 7.6.2 Gilead Business Overview 7.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.6.5 Gilead Recent Development 7.7 Horizon Pharma 7.7.1 Horizon Pharma Company Details 7.7.2 Horizon Pharma Business Overview 7.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.7.5 Horizon Pharma Recent Development 7.8 Immuron 7.8.1 Immuron Company Details 7.8.2 Immuron Business Overview 7.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.8.5 Immuron Recent Development 7.9 Intercept Pharmaceuticals 7.9.1 Intercept Pharmaceuticals Company Details 7.9.2 Intercept Pharmaceuticals Business Overview 7.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.9.5 Intercept Pharmaceuticals Recent Development 7.10 Novo Nordisk 7.10.1 Novo Nordisk Company Details 7.10.2 Novo Nordisk Business Overview 7.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 7.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) 7.10.5 Novo Nordisk Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends Table 3. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers Table 4. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges Table 5. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Player, 2017-2022 Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2021) Table 15. Top Players of Non-Alcoholic Steatohepatitis (NASH) Drugs in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in United States Market, Ranking by Revenue (2021) Table 20. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 30. AstraZeneca Company Details Table 31. AstraZeneca Business Overview Table 32. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 33. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 34. AstraZeneca Recent Development Table 35. Conatus Pharmaceuticals Company Details Table 36. Conatus Pharmaceuticals Business Overview Table 37. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 38. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 39. Conatus Pharmaceuticals Recent Development Table 40. Enzo Biochem Company Details Table 41. Enzo Biochem Business Overview Table 42. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 43. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 44. Enzo Biochem Recent Development Table 45. Galmed Pharmaceuticals Company Details Table 46. Galmed Pharmaceuticals Business Overview Table 47. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 48. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 49. Galmed Pharmaceuticals Recent Development Table 50. Genfit Company Details Table 51. Genfit Business Overview Table 52. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 53. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 54. Genfit Recent Development Table 55. Gilead Company Details Table 56. Gilead Business Overview Table 57. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 58. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 59. Gilead Recent Development Table 60. Horizon Pharma Company Details Table 61. Horizon Pharma Business Overview Table 62. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 63. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 64. Horizon Pharma Recent Development Table 65. Immuron Company Details Table 66. Immuron Business Overview Table 67. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 68. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 69. Immuron Recent Development Table 70. Intercept Pharmaceuticals Company Details Table 71. Intercept Pharmaceuticals Business Overview Table 72. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 73. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 74. Intercept Pharmaceuticals Recent Development Table 75. Novo Nordisk Company Details Table 76. Novo Nordisk Business Overview Table 77. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Table 78. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Table 79. Novo Nordisk Recent Development Table 80. Research Programs/Design for This Report Table 81. Key Data Information from Secondary Sources Table 82. Key Data Information from Primary Sources List of Figures Figure 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Product Picture Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size 2017-2028 (US$ Million) Figure 4. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size 2017-2028 (US$ Million) Figure 6. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share in Global 2017-2028 Figure 7. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered Figure 8. Product Picture of Vitamin E & Pioglitazone Figure 9. Product Picture of Obeticholic Acid (OCA) Figure 10. Product Picture of Elafibranor Figure 11. Product Picture of Selonsertib & Cenicriviroc Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type in 2022 & 2028 Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028) & (US$ Million) Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028) Figure 15. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type in 2022 & 2028 Figure 16. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028) & (US$ Million) Figure 17. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028) Figure 18. Product Picture of Hospital Pharmacy Figure 19. Product Picture of Online Provider Figure 20. Product Picture of Retail Pharmacy Figure 21. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2022 & 2028 Figure 22. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028) & (US$ Million) Figure 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028) Figure 24. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2022 & 2028 Figure 25. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028) & (US$ Million) Figure 26. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028) Figure 27. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 28. U.S. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 30. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 31. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 37. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Taiwan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Indonesia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Thailand Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Malaysia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Philippines Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 48. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 52. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. U.A.E Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 55. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 56. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 57. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 58. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 59. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 60. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 61. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 62. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 63. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 64. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) Figure 65. Bottom-up and Top-down Approaches for This Report Figure 66. Data Triangulation Figure 67. Key Executives Interviewed

AstraZeneca Conatus Pharmaceuticals Enzo Biochem Galmed Pharmaceuticals Genfit Gilead Horizon Pharma Immuron Intercept Pharmaceuticals Novo Nordisk